Individuals with loss-of-function (LOF) mutations in PCSK9 exhibit higher levels of liver LDLR, leading to lower LDL-C levels and a 50 to 86% decrease in the lifetime risk of CAD relative to non-mutation bearers [110]. The gene discussed is PCSK9; the disease is coronary artery disorder.